AnaptysBio, Inc.

NasdaqGS:ANAB 株式レポート

時価総額:US$644.2m

AnaptysBio 配当と自社株買い

配当金 基準チェック /06

AnaptysBio配当金を支払った記録がありません。

主要情報

n/a

配当利回り

-15.6%

バイバック利回り

総株主利回り-15.6%
将来の配当利回り0%
配当成長n/a
次回配当支払日n/a
配当落ち日n/a
一株当たり配当金n/a
配当性向n/a

最近の配当と自社株買いの更新

Recent updates

AnaptysBio: An Immunology Pipeline-In-A-Pill Company Worth Watching

Nov 21

AnaptysBio, Inc. (NASDAQ:ANAB) May Have Run Too Fast Too Soon With Recent 33% Price Plummet

Nov 07
AnaptysBio, Inc. (NASDAQ:ANAB) May Have Run Too Fast Too Soon With Recent 33% Price Plummet

AnaptysBio: Too Risky, Especially After GSK Drops Its Related Programs

Nov 01

AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point

Aug 15

AnaptysBio: Interesting Prospects, But Wait For The Dip (Rating Downgrade)

Jul 08

News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

May 22
News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

May 12
Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?

Feb 22
Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Oct 10
Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%

May 24
AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%

Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?

Apr 27
Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Jan 10
Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

AnaptysBio benefits from results of GSK mid-stage Jemperli combo lung cancer trial

Oct 05

Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher

Sep 14
Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher

AnaptysBio sells royalties from GSK-partnered Zejula for $45M

Sep 12

AnaptysBio (NASDAQ:ANAB) Is In A Good Position To Deliver On Growth Plans

Sep 01
AnaptysBio (NASDAQ:ANAB) Is In A Good Position To Deliver On Growth Plans

AnaptysBio skin condition candidate fails mid-stage trial; shares down 16%

Aug 31

AnaptysBio GAAP EPS of -$1.15 misses by $0.14, revenue of $1.21M misses by $4.4M

Aug 08

Some AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Made A Major Cut To Next Year's Estimates

May 10
Some AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Made A Major Cut To Next Year's Estimates

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Mar 16
Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

AnaptysBio's (NASDAQ:ANAB) Performance Is Even Better Than Its Earnings Suggest

Nov 11
AnaptysBio's (NASDAQ:ANAB) Performance Is Even Better Than Its Earnings Suggest

決済の安定と成長

配当データの取得

安定した配当: ANABの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: ANABの配当金が増加しているかどうかを判断するにはデータが不十分です。


配当利回り対市場

AnaptysBio 配当利回り対市場
ANAB 配当利回りは市場と比べてどうか?
セグメント配当利回り
会社 (ANAB)n/a
市場下位25% (US)1.4%
市場トップ25% (US)4.3%
業界平均 (Biotechs)2.3%
アナリスト予想 (ANAB) (最長3年)0%

注目すべき配当: ANABは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: ANABは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。


株主への利益配当

収益カバレッジ: ANABの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。


株主配当金

キャッシュフローカバレッジ: ANABが配当金を報告していないため、配当金の持続可能性を計算できません。


高配当企業の発掘